Michael Gilman retired when Padlock Therapeutics was bought out, but now he’s back to helm a company promising to transform cell and gene therapies.

Now well established across the U.S. and Canada, J&J’s biotech incubator system has expanded into Asia with its first center in China.

PayPal founder Peter Thiel and VC OrbiMed’s Israel unit have helped ChemomAb raise $10 million in a series B round.

The fund will reportedly embark on the spending spree while shifting a “significant” chunk of its operations from the U.S. to the U.K.

Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.

The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.

The series A positions the startup, Mavupharma, to further its work on the use of oral STING modulators to treat cancer and infectious diseases.

AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.